Project description
Application of bioengineered resveratrol in new anticancer therapy concepts
Resveratrol is a natural polyphenol of plant origin that acts against pathogens, including bacteria and fungi. Funded by the Marie Skłodowska-Curie Actions programme, the p53-REACT project aims to engineer a bacterial host to produce resveratrol metabolite variants and study their interaction with the tumour suppressor protein p53. The objective is to elucidate the mode of action of resveratrol molecules on the p53 mutants with a focus on new concepts for cancer therapy. The project represents a broad study of the resveratrol derivatives acting as p53 aggregation inhibitors and involves cutting-edge computational resources and metabolic and structural bioengineering.
Fields of science
- engineering and technologyindustrial biotechnologymetabolic engineering
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health sciencesclinical medicineoncology
- medical and health sciencesbasic medicinepathology
- natural sciencesbiological sciencesmolecular biologystructural biology
Programme(s)
- HORIZON.1.2 - Marie Skłodowska-Curie Actions (MSCA) Main Programme
Funding Scheme
HORIZON-AG-UN - HORIZON Unit GrantCoordinator
TECHNISCHE UNIVERSITAET MUENCHEN
Net EU contribution
€ 189 687,36
Address
Arcisstrasse 21
80333 Muenchen
Germany
80333 Muenchen
Germany
See on map
Region
Bayern Oberbayern München, Kreisfreie Stadt
Activity type
Higher or Secondary Education Establishments
Other funding
No data
Partners (1)
Rensselaer Polytechnic Institute
United States
Net EU contribution
€ 0,00
Address
8th Street 110
12180 Troy
12180 Troy
See on map
Activity type
Higher or Secondary Education Establishments
Other funding
No data